在欧洲 (2015-2019) 实践中使用伊萨夫可纳的有效性,安全性和使用模式 (2015-2019)
Dionysios Neofytos1, Antonio Pagliuca2, Katherine Houghton3
1Geneva University Hospitals, Geneva, Switzerland.
Infectious diseases and therapy
|October 23, 2024
概括
伊萨夫可纳在欧洲患有侵袭性阿斯伯吉洛症 (IA) 或侵袭性粘膜菌病 (IM) 的患者中显示出有前途的临床反应和良好的安全性. 这些真实数据支持其作为这些严重的真菌感染的初级或救援疗法.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 要评估其临床性能,需要在欧洲对伊萨武可纳使用的真实数据.
- 了解伊萨武科纳在治疗侵袭性真菌感染 (IFI) 中的作用,如侵袭性阿斯伯吉洛症 (IA) 和侵袭性粘膜炎 (IM),至关重要.
研究的目的:
- 评估伊萨夫可纳在欧洲患者中的实际有效性和安全性.
- 分析临床响应率,整体存活率和与IA和IM治疗伊萨武可纳相关的不良事件.
主要方法:
- 在16个欧洲地点对218名患者的病历进行了回顾性审查.
- 纳入标准:年龄≥18岁的患者在2015年10月至2019年6月期间因疑似/确诊的IA或IM而接受至少一剂伊萨武科纳.
- 临床反应,生存和不良事件的描述性分析.
主要成果:
- 伊萨夫可纳作为单疗法在218名患者 (201IA,17IM) 中使用,作为初级 (42.2%) 或救援 (55.5%) 治疗开始.
- 在第24周的临床反应估计为初级治疗的54.5%和救援治疗的73.5%.
- 21%的患者出现了不良事件 (AE);17%的患者出现了严重的AE,而2.3%的患者由于严重的AE而停止治疗. 总体死亡率为63%.
结论:
- 伊萨夫可纳在欧洲实践中显示出有前途的临床反应和良好的安全性.
- 这项研究支持isavuconazole作为入侵性阿斯伯吉洛症和入侵性粘性菌的第一线和救援疗法的疗效.
- 这些发现有助于证据基础的isavuconazole的实用性在不同的患者群体严重的真菌感染.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
05:46Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.8K
相关概念视频
01:28Antimicrobial Effectiveness
2
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2
01:19Pharmacovigilance
778
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
778
01:26Drug Administration and Therapy Phases: Overview
412
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
412
01:14Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
01:21Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
397
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
397